ArticleScientific reports2026
Analysing cell death patterns to predict outcomes and treatment options in patients with high-grade serous ovarian carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
High-grade serous ovarian carcinoma (HGSOC) is a gynaecological malignancy that is often fatal. Poor prognosis of HGSOC patients is primarily attributed to concealed initial symptoms, diagnostic challenges, postsurgical recurrence , and chemoresistance. Distinct programmed cell death (PCD) patterns play a pivotal role in tumour progression, serving as valuable predictors for postoperative intervention outcomes in HGSOC. Additionally, they provide insights into HGSOC’s pathogenesis and the exploration of immunomodulatory therapeutic mechanisms. Transcriptome and clinical data were collected from TCGA-OV and the GSE26193 databases. We constructed an ovarian carcinoma death score intervention model using eight genes and machine learning algorithms based on 13 PCD modes (apoptosis, necroptosis, pyroptosis, cuproptosis, ferroptosis,entotic cell death, netotic cell death, parthanatos, lysosome-dependent cell death, autophagy, alkaliptosis, oxeiptosis, and disulfidptosis). Three molecular subtypes of HGSOC with different biological processes were identified using unsupervised clustering models. A nomogram was constructed by combining the cell death index (CDI) with clinical features, which exhibited high predictive performance. The correlation between CDI and immune checkpoint genes, components within the tumour microenvironment, and drug therapy sensitivity was analysed. After multiple dataset validation, the prognosis of HGSOC patients with high CDI was relatively poor. CDI and immune checkpoint genes were related to components of the tumour microenvironment. Patients with HGSOC and high CDI may have resistance to standard adjuvant therapy; therefore, targeting these genes could be a potential therapeutic strategy. Finally, we found that our model had better predictive ability than published models. We conducted a comprehensive analysis of 13 PCD patterns and established a novel CDI model, which can evaluate the prognosis of HGSOC and provide a theoretical basis for its clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.